PTC Therapeutics, Inc. PTCT

PTCT Company Overview

PTC Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of medicines for rare disorders and conditions with high unmet medical need. The company operates within the biotechnology and pharmaceutical industries, with a core emphasis on genetic, neuromuscular, metabolic, and neurodegenerative diseases. Its business model combines internal research and development with strategic collaborations to advance therapies from discovery through commercialization.

PTC Therapeutics’ primary revenue drivers include sales of approved therapies, milestone payments, and collaboration-related revenues. Key marketed products include Translarna, Upstaza, and Evrysdi (the latter through a global collaboration). The company is recognized for its expertise in RNA biology and small-molecule drug discovery, particularly therapies designed to target the underlying genetic causes of disease. Founded in 1998, PTC Therapeutics evolved from an early-stage research company into a commercial-stage organization following regulatory approvals in Europe and select international markets, while continuing to expand its clinical pipeline.